US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

(New York Times) A small randomized trial in China showed that transcutaneous auricular vagus nerve stimulation improved ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

纽约 - 市值5.4852亿美元的临床阶段生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)今日宣布,其用于治疗广泛性焦虑障碍 (GAD)的实验性药物MM120 ODT已获得英国药品和保健品监管局 (MHRA)颁发的创新通行证。根据InvestingPro的数据,该公司今年以来的股价表现出色,年初至今涨幅超过104%。这一认证是创新许可和准入途径 ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...

Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的董事David W. Gryska最近购入了该公司2,500股普通股。这笔交易发生于2024年12月5日，每股价格为7.17美元，总投资额为17,925美元。这次购买的时机值得注意，因为根据InvestingPro的数据，该股票在过去一年里表现强劲，回报率高达114%。此次交易后，Gryska目前直接持有Mind ...

Check the time stamp on this data. Updated AI-Generated Signals for Mind Medicine (mindmed) Inc. (MNMD) available here: MNMD.

Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...